1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

The registered record

Accession number

NCT06926023

Lead sponsor

Goldman, Butterwick, Fitzpatrick and Groff (other)

Registered condition naming hair loss

Female Pattern Baldness

Official title

A Prospective, Randomized, Evaluator-blind, Clinical Trial Evaluating the 1550nm Non-ablative Fractional or 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss

Interventions

• Device1550nm non-ablative fractional laser
• Device1927 thulium fractional laser

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Not applicable

Allocation

randomized

Masking

single

Primary purpose

treatment

Enrolment

10 participants (estimated)

Sites

1 location in United States

What it measures

1. Change in hair count at a predefined 1cm x 1cm scalp location

   Time frame: Baseline and Day 180

2. Change in hair density (hairs/cm) at the same predefined scalp area

   Time frame: Baseline and Day 180

3. Change in terminal hair average diameter (in mm) at the predefined location

   Time frame: Baseline and Day 180

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

female

Age

35 Years to 65 Years

Healthy volunteers

accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

1 May 2025 (estimated)

Primary completion

30 November 2025 (estimated)

Study completion

31 December 2025 (estimated)

First posted

13 April 2025 (actual)

Last update posted

16 April 2025 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: this record registers a primary completion to the day, so a day is what is shown. Where a sponsor registers only a month, only a month is shown.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Androgenetic Alopecia: Complete GuideNew Hair Loss Treatments in Clinical Trials: Clascoterone, Pyrilutamide and What the Published Data Actually ShowComplete Guide to Finasteride for Hair LossMinoxidil 5% Complete Guide: How to Apply for Best ResultsFemale Pattern Hair Loss: Treatment Options That WorkWomen's Hair Loss: The Complete GuideSpironolactone for Hair Loss in WomenDiffuse Thinning vs. Pattern Baldness: How to Tell the Difference (2026 Guide)How to Tell If You're Going Bald: Early Signs & Self-Assessment Guide (2026)

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT06926023 on ClinicalTrials.gov · All 157 trials in the pipeline